Infectious Vaccines Partnering Market @ http://www.researchmoz.us/infectious-vaccines-partnering-terms-and-agreements-report.html The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

1. Infectious Vaccines Partnering Terms and Agreements
The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and
analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are
development stage whereby the licensee obtains a right or an option right to license the licensors vaccine
technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization
of outcomes. The report also includes adjuvant deals and alliances. This report provides details of the latest
infectious vaccines agreements announced in the healthcare sectors. Understanding the flexibility of a
prospective partner’s negotiated deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will
be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered
– contract documents provide this insight where press releases and databases do not. This report
contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007,
including financial terms where available, including over 700 links to online deal records of actual infectious
vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include
contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a significant impact on each
party’s ability to derive value from the deal. For example, analyzing actual company deals and
agreements allows assessment of the following: What is actually granted by the agreement to the partner
company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment
structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of
the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is
responsible for development, supply, and manufacture? How is confidentiality and publication managed? How
are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a
change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate
clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial
chapters of this report provide an orientation of infectious vaccines dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2007, including details
of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the
leading infectious vaccines deals since 2007. Deals are listed by headline value. Where the deal has an
agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a
comprehensive listing of the top 50 big pharma companies for which deals are available, with a brief summary
followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in
the public domain. Where available, each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on demand. Chapter 5 provides a
comprehensive listing of the big biotech companies for which deals are available, with a brief summary
followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in
Infectious Vaccines Partnering Terms and Agreements

2. the public domain. Where available, each deal title links via Weblink to an online version of the actual
contract document, providing easy access to each contract document on demand. Chapter 6 provides a
comprehensive and detailed review of infectious vaccines partnering deals signed and announced since
January 2007, where a contract document is available in the public domain. The chapter is organized by
company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc),
specific therapy focus and specific technology type focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document, providing easy access to each contract
document on demand. The report also includes numerous tables and figures that illustrate the trends and
activities in infectious vaccines partnering and dealmaking since 2007.
In
conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of infectious vaccines technologies and products.. Report
scope
Infectious Vaccines Partnering Agreements is intended to provide the reader with an in-depth understanding
and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.
Infectious Vaccines Partnering Agreements includes:
Trends in infectious vaccines dealmaking in the biopharma industry since 2007 Analysis of infectious
vaccines deal structure Access to headline, upfront, milestone and royalty data Access to over 700 infectious
vaccines deal records The leading infectious vaccines deals by value since 2007 Includes adjuvant deals and
alliances since 2007 In Infectious Vaccines Partnering Agreements, the available deals are listed by:
Company A-Z Headline value Stage of development at signing Deal component type Specific infectives
therapy target Each deal title links via Weblink to an online version of the deal record and where available,
the contract document, providing easy access to each contract document on demand.
table Of Contents
executive Summary
chapter 1 – Introduction
chapter 2 – Trends In Infectious Vaccines Dealmaking
2.1. Introduction
2.2. Infectious Vaccines Partnering Over The Years
2.3. Big Pharma Infectious Vaccines Dealmaking Activity
2.4. Big Biotech Infectious Vaccines Dealmaking Activity
2.4. Most Active In Infectious Vaccines Partnering
2.5. Infectious Vaccines Partnering By Deal Type
2.6. Infectious Vaccines Partnering By Stage Of Development
2.7. Infectious Vaccines Partnering By Infectives Indication
2.8. Infectious Vaccines Partnering By Vaccine And Adjuvant Indication
2.9. Disclosed Deal Terms For Infectious Vaccines Partnering
Infectious Vaccines Partnering Terms and Agreements

3. 2.9.1 Infectious Vaccines Partnering Headline Values
2.9.2 Infectious Vaccines Deal Upfront Payments
2.9.3 Infectious Vaccines Deal Milestone Payments
2.9.4 Infectious Vaccines Royalty Rates
2.10. The Anatomy Of Infectious Vaccines Partnering
2.10. The Anatomy Of A Infectious Vaccines Deal
2.10.a. Case Study 1: Gilead Sciences, Globeimmune- Oct 24 2011
2.10.b. Case Study 2: Astellas, Vical: July 14, 2011
chapter 3 – Leading Infectious Vaccines Deals
3.1. Introduction
3.2. Top Infectious Vaccines Deals By Value
chapter 4 – Bigpharma Infectious Vaccines Deals
4.1. Introduction
4.2. How To Use Bigpharma Partnering Deals
4.3. Big Pharma Infectious Vaccines Partnering Company Profiles
abbott
astellas
astrazeneca
baxter International
bayer
csl
daiichi Sankyo
eisai
gilead Sciences
glaxosmithkline
johnson & Johnson
kyowa Hakko Kirin
merck & Co
mitsubishi Tanabe
novartis
pfizer
roche
sanofi
shionogi
takeda
chapter 5 – Big Biotech Infectious Vaccines Deals
5.1. Introduction
Infectious Vaccines Partnering Terms and Agreements

4. 5.2. How To Use Big Biotech Partnering Deals
5.3. Big Biotech Infectious Vaccines Partnering Company Profiles
bavarian Nordic
cangene
emergent Biosolutions
chapter 6 – Infectious Vaccines Dealmaking Directory
6.1. Introduction
6.2. Company A-z
3m
a*star Agency For Science, Technology And Research
a*star Bioprocessing Technology Institute
a*star Singapore Immunology Network
aaron Diamond Aids Research Center
abbott Laboratories
aberystwyth University
absynth Biologics
academia Sinica
acambis
accelovance
ace Biosciences
achaogen
adimmune
aduro Biotech
advanced Bionutrition
advanced Bioscience Laboratories
advanced Immunization Technologies (aditec)
advaxis
aeras Global Tb Vaccine Foundation
affiris
agenus Bio
agilent Technologies
ajanta Pharma
akorn
akshaya Bio
albany Medical College
albert Einstein College Of Medicine
aldevron
alexis Biotech
algonomics
alk-abello
allied Healthcare Group
Infectious Vaccines Partnering Terms and Agreements

5. alnylam Pharmaceuticals
alphavax
althea Technologies
altravax
american Type Culture Collection (atcc)
amvac
amyris Biotechnologies
anc Bio
anges Mg
antelope Valley Biologics
antigen Discovery
antigen Express
antigenics
antitope
apogee Biotechnology
apotex
archimedes Development
archimedes Pharma
arecor
argos Therapeutics
ariad Pharmaceuticals
ariavax
arizona State University
ark Therapeutics
artepharm Co
artepharm Global
artes Biotechnology
astellas Pharma
astellas Pharma Us
astrazeneca
astrogenetix
atreca
australian Centre For Vaccine Development
australian National University
avac
avant Immunotherapeutics
avecia Biologics
avi Pharma
avid Bioservices
avimex
barr Pharmaceuticals
battelle
bavarian Nordic
Infectious Vaccines Partnering Terms and Agreements

6. baxter International
bayer
beijing Health Bureau
beijing Tiantan Biological Products
beth Israel Deaconess Medical Center
biken
bill And Melinda Gates Foundation
binnopharm
bio-manguinhos
bioalliance Pharma
biocryst Pharmaceuticals
biodiem
biofactura
bioject Medical Technologies
biolik Biopharmaceutical
biological E
biomedical Advanced Research And Development Authority
biondvax
bioniche Life Sciences
bionor Pharma
biopharm Services
bioreliance
biota
biotechnology And Biological Sciences Research Council (bbsrc)
bioveris
biovest
birmex
boryung Pharmaceutical
brigham Young University
butantan Institute
cadila Pharmaceuticals
cambridge Biostability
cangene
capsulation Nanoscience
carrington Laboratories
case Western Reserve University
catherex
catholic University Of America
celldex Therapeutics
cellectis Bioresearch
centegen
centers For Disease Control And Prevention
centre National De Recherche Et De Formation Sur Le Paludisme
Infectious Vaccines Partnering Terms and Agreements

7. centro De Investigacion Y Asistencia Tecnologica Y Diseno Del Estado De Jalisco
centrovet
centrovet Laboratories
ceva Sante Animale
cevec Pharmaceuticals
changchun Bcht Biotechnology
chemrar High-tech Center
chengdu Institute Of Biological Products
cheyney University
china Centre For Disease Control
china National Biotech Group (cnbg)
chinese Center For Disease Control And Prevention
chinese Federal Government
chongqing Zhifei Biological Products
chrontech Pharma
chumakov Institute Of Poliomyelitis And Viral Encephalitides
clintec International
cobra Biologics
coley Pharmaceutical Group
colorado Institute For Drug, Device And Diagnostic Development
compass Biotechnologies
corgenix Medical
cpl Biologicals
critical Path Institute (c-path)
crossbeta Biosciences
crucell
crucible International Biotechnologies
csiro
csl
csl Biotherapies
curevac
cytodyn
cytogenix
cytos Biotechnology
cyvax
daiichi Pharmaceutical
daiichi Sankyo
dalton Pharma Services
dana-farber Cancer Institute
danish Defence
dartmouth College
dbv Technologies
defence Research And Development Canada
Infectious Vaccines Partnering Terms and Agreements

8. defense Advanced Research Projects Agency
defense Threat Reduction Agency
defyrus
delphi Genetics
delsite
department Of Defense
department Of Health And Human Services
department Of Homeland Security
diagnostic Hybrids
dor Biopharma
drexel University
dri Capital
drugs For Neglected Diseases Initiative
duke-nus Graduate Medical School Singapore
duke University
duke University Medical Center
dynavax Technologies
dynport Vaccine Company
eden Biodesign
eisai
elanco
emcure Pharmaceuticals
emd Millipore
emergent Biosolutions
emergent Product Development
emory University
encorium Group
endobiologics
enwave
epic Bio
epicept
epitopix
erasmus University Medical Center
esteve
european Commission
european Union
european Vaccine Initiative
evolutec
evolva
exploit Technologies
expres2ion Biotechnologies
fabentech
fina Biosolutions
Infectious Vaccines Partnering Terms and Agreements

9. fit Biotech
flugen
food And Drug Administration (fda)
formatech
fort Dodge Animal Health
fourth Military Medical University
fraunhofer Usa
fraunhofer Usa Center For Molecular Biotechnology
french National Institute For Agricultural Research
french National Research Agency
fusion Ip
g-con
gador
gamma Vaccines
ge Healthcare
geneart
generex Biotechnology
genethera
genetic Immunity
genocea Biosciences
genomidea
genphar
genvec
geovax
german Cancer Research Center
gilead Sciences
glaxosmithkline
glaxosmithkline Biologicals
glide
global Green
globeimmune
glycomimetics
glycosensors And Diagnostics
glycovaxyn
gni
goodwin Biotechnology
government Of Canada
government Of China
government Of India
government Of Japan
government Of United Kingdom
green Cross
harbin Pharmaceutical Group
Infectious Vaccines Partnering Terms and Agreements

10. harrisvaccines
harvard Medical School
harvard University
hawaii Biotech
health Protection Agency (hpa)
heat Biologics
helmholtz Centre For Infection Research
hemispherx Biopharma
henderson Morley
henry Schein
hiv Vaccine Trials Network (hvtn)
hollister-stier Labs
hunan Biopharmaceutical
ibio
ibiopharma
ichor Medical Systems
icon Genetics
id Biomedical
ihi
ihi Plant Engineering Corporation
imaxio
immbio
immune Design
immuneregen Biosciences
immunomedics
immunovaccine
immunovaccine Technologies
imperial Innovations
imugene
in Cell Art
inclinix
infectious Disease Research Institute (idri)
inovio Biomedical
inovio Pharmaceuticals
inserm
institut Pasteur
institute For Medical Microbiology, Immunology And Hygiene (immih)
institute For Oneworld Health
integrated Biopharma
integrated Biotherapeutics
intercell
international Aids Vaccine Initiative
international Center For Genetic Engineering And Biotechnology
Infectious Vaccines Partnering Terms and Agreements

11. international Medica Foundation
international Vaccine Institute (ivi)
intervet
inviragen
invitria
iomai
ippox Foundation
iq Products
iqur
irsicaixa Aids Research Institute
isconova
istituto Superiore Di Sanita
italian Government
janssen Pharmaceutica Nv
janssen Pharmaceutical
jantibody Therapeutics
japan Government
jenner Institute
jiangsu Walvax
johns Hopkins University
johnson & Johnson
jsc Binnopharm
juvaris Biotherapeutics
kaketsuken
karolinska Institute
kirin Pharma
kitasato Daiichi Sankyo Vaccine
kitasato Institute
kyoto Biken
kyowa Hakko Kirin
la Jolla Institute For Allergy & Immunology
lallemand Pharma Europe
lebanese-canadian Hospital
leiden University
leidos Holdings
lentigen
lg Life Sciences
ligocyte Pharmaceuticals
lipotek
lipoxen
liquidia Technologies
lohmann Animal Health
lonza
Infectious Vaccines Partnering Terms and Agreements

12. lovelace Respiratory Research Institute
lucigen
mahidol University
maryland Technology Development Corporation
massachusetts Biologic Laboratories
massachusetts General Hospital
massbiologics
max-planck
max Planck Institute For Dynamics Of Complex Technical Systems
maxcyte
maxygen
mayo Clinic
mcmaster University
medicago
medicine In Need
medicines For Malaria Venture
medigene
medimmune
medison Pharma
mellow Hope Bio Chem
merck And Co
merial
meridian Bioscience
meridian Life Science
merix Bioscience
metabolon
microbix Biosystems
military Hiv Research Program (mhrp)
ministry Of Defence
ministry Of Health Of Brazil
mitsubishi Tanabe Pharma
mologen
monash University
monosol Rx
mount Sinai School Of Medicine
mpi Research
msd Wellcome Trust Hilleman Laboratories
mucosis
mymetics
nabi Biopharmaceuticals
nanobio
nanotherapeutics
nanoviricides
Infectious Vaccines Partnering Terms and Agreements

13. narvac
nasa
nasvax
national Cancer Institute
national Health And Medical Research Council
national Healthcare Services (nhs)
national Institute Of Allergy And Infectious Diseases
national Institute Of Infectious Diseases
national Institute Of Nanotechnology
national Institute On Drug Abuse (nida)
national Institutes Of Health
national Microbiology Laboratory
national Research Council Canada
national University Of Singapore
naval Medical Research Center
navy Medical Research Centre
netherlands Vaccine Institute
neugenesis
new York Medical College
niigata Tlo/nbrp/kutlo-nitt
ninebio
ninesigma
nobilon
noguchi Memorial Institute For Medical Research
north West Fund
novartis
novartis Vaccines
novation
novavax
novozymes
numerate
nuron Biotech
nyu Langone Medical Center
omnia Biologics
omnivest
opal Therapeutics
opko Health
opsona Therapeutics
ortho-mcneil-janssen Pharmaceuticals
ortho-mcneil
oseo
oswaldo Cruz Foundation
oswaldo Cruz Foundation (fiocruz)
Infectious Vaccines Partnering Terms and Agreements

14. oxford- Emergent Tuberculosis Consortium
oxford Biomedica
pacificgmp
paladin Labs
pan-provincial Vaccine Enterprise
pan American Health Organization
paragon Bioservices
parenteral Biotech
path (appropriate Technology In Health)
path Malaria Vaccine Initiative
paxvax
pecet
pediatric Dengue Vaccine Initiative
pennsylvania Department Of Health
pepscan Therapeutics
peptcell
peptimmune
peptivir
pevion
pfenex
pfizer
pfizer Animal Health
pharmajet
pharmaq
pharmathene
pharmexa
pharmsynthez
philip Morris Products
ploughshare Innovations
ppd
preclin Biosystems
presido Pharmaceuticals
prevtec Microbia
probiogen
profectus Biosciences
prokarium
protein Potential
protein Sciences
protherics
psioxus Therapeutics
public Health Agency Of Canada
purdue Research Foundation
qiagen
Infectious Vaccines Partnering Terms and Agreements

15. radboud University Nijmegen Medical Centre
ragon Institute
rapid Micro Biosystems
ratio
receptor Logic
redbiotec
regenx Biosciences
replikun Biotech
research Council Of Norway
rhapsody Biologics
riboxx Pharmaceuticals
roche
romark Laboratories
rovi Pharmaceuticals
sabin Vaccine Institute
saic-frederick
sanaria
sanofi-aventis
sanofi-pasteur
sanofi
sanofi Pasteur Kk
saskatchewan Research Council
scancell
scarab Genomics
schering-plough
scigen
scripps Research Institute
seattle Biomed
seek
select Vaccines
selecta Biosciences
sentry Biopharma
sepragen
serum Institute Of India
shanghai Bravobio
shanghai Centers For Disease Control And Prevention
shantha Biotechnics
shenzhen Neptunus Interlong Bio-technique
shionogi
siga Technologies
sinobiomed
sinovac Beijing
sinovac Biotech
Infectious Vaccines Partnering Terms and Agreements

16. sk Chemicals
skystar Biopharmaceutical
small Business Innovation Research
soligenix
sorrento Therapeutics
southern Research Institute
sri International
stabilitech
statens Serum Institute
stellar Biotechnologies
sumagen
swiss Tropical And Public Health Institute
symphony Dynamo
synthetic Genomics Vaccines
syntiron
synvolux Therapeutics
taiwan Cobia
takeda Pharmaceutical
talecris Biotherapeutics
tapimmune
tasly Pharmaceuticals
tb Alliance
td Vaccines
technology Strategy Board
technovax
telormedix
temasek Life Sciences
terumo
tetragenetics
the International Aids Vaccine Initiative
the Qater Foundation
tianjin Cansino Biotechnology
tno Pharma
top Institute Pharma
torii Pharmaceutical
transgene
trius Therapeutics
tuberculosis Vaccine Initiative
tulane University
uk Government
uk Hiv Vaccine Consortium
umn Pharma
uniformed Services University Of The Health Sciences
Infectious Vaccines Partnering Terms and Agreements

17. uniquest
united Biomedical
united Nations
united Nations Children Fund
united States Agency For International Development
universidad De Los Andes
university Of Adelaide
university Of Birmingham
university Of British Columbia
university Of California, Davis
university Of California
university Of Canberra
university Of Chicago
university Of Colorado
university Of Connecticut
university Of Copenhagen
university Of Guelph
university Of Kansas
university Of Maryland
university Of Maryland Biotechnology Institute
university Of Maryland School Of Medicine
university Of Maryland Ventures
university Of Massachusetts
university Of Massachusetts Medical School
university Of Medicine And Dentistry Of New Jersey
university Of Melbourne
university Of Miami Miller School Of Medicine
university Of Michigan
university Of Minnesota
university Of New Mexico
university Of North Carolina
university Of Oxford
university Of Pennsylvania
university Of Pittsburgh
university Of Queensland
university Of Rochester
university Of Rouen
university Of Texas
university Of Texas At El Paso
university Of Texas Medical Branch
university Of Utah
university Of Washington
university Of Wisconsin
Infectious Vaccines Partnering Terms and Agreements

18. us Army
us Army Medical Research Institute Of Infectious Diseases
us Government
vabiotech
vaccibody
vaccine And Gene Therapy Institute Of Florida (vgti-fl)
vaccine Technologies
vakzine Projekt Management
vandalia Research
vaxdesign
vaxent
vaxgen
vaxin
vaxinnate
vet Cure Pharma
vgx Pharmaceuticals
vibalogics
vical
vichem Chemie
victorian College Of Pharmacy
viral Genetics
virbac
virexx
virginia Commonwealth University
virogen
virosome Biologicals
virostatics
vitamfero
vivaldi Biosciences
vivalis
wageningen University
walter And Eliza Hall Institute
walter Reed Army Institute Of Research
wellcome Trust
wistar Institute
wittycell
world Bank
world Health Organization
wyeth
xcellerex
xiamen University
xoma
xtl Biopharmaceuticals
Infectious Vaccines Partnering Terms and Agreements

19. yokohama City University
ypsomed
yunnan Walvax Biotech
zydus Cadila
6.3. By Deal Type
asset Purchase
assignment
bigpharma Outlicensing
co-development
collaborative R&d
co-market
contract Service
co-promotion
crada
cross-licensing
development
distribution
equity Purchase
evaluation
grant
joint Venture
licensing
litigation
manufacturing
manufacturing - Oem
marketing
material Transfer
option
promotion
research
settlement
spin Out
sub-license
supply
technology Transfer
termination
warranty
6.4. By Stage Of Development
discovery
formulation
marketed
Infectious Vaccines Partnering Terms and Agreements

20. phase I
phase Ii
phase Iii
preclinical
regulatory
6.5. By Infectives Therapy Area
6.5. By Vaccine And Adjuvant Technology Area
vaccines
adjuvant
chapter 7 –partnering Resource Center
7.1. Online Partnering
7.2. Partnering Events
7.3. Further Reading On Dealmaking
appendices
appendix 1 – Deal Type Definitions
about Wildwood Ventures
current Partnering
current Agreements
recent Report Titles From Currentpartnering
order Form – Therapy Reports
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Infectious Vaccines Partnering Terms and Agreements

21. Website: http://www.researchmoz.us/
Infectious Vaccines Partnering Terms and Agreements